| 1 |
32741700 | Targeting p53 for the treatment of cancer. | 2022 Feb |
1 |
| 2 |
34861697 | Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. | 2022 Feb 8 |
1 |
| 3 |
34933330 | The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. | 2022 Feb 22 |
2 |
| 4 |
34937801 | Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions. | 2022 Mar |
1 |
| 5 |
35179215 | Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors. | 2022 Mar |
4 |
| 6 |
35413116 | Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial. | 2022 Apr 12 |
1 |
| 7 |
35420431 | Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells. | 2022 Apr 28 |
1 |
| 8 |
35440992 | Catalytic asymmetric synthesis of enantioenriched α-deuterated pyrrolidine derivatives. | 2022 Apr 6 |
2 |
| 9 |
33190064 | Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses. | 2021 Jan |
1 |
| 10 |
33668835 | Pharmacological Activation of p53 during Human Monocyte to Macrophage Differentiation Attenuates Their Pro-Inflammatory Activation by TLR4, TLR7 and TLR8 Agonists. | 2021 Feb 25 |
2 |
| 11 |
33850004 | High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells. | 2021 Jun |
1 |
| 12 |
34180037 | Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. | 2021 Dec |
3 |
| 13 |
34732238 | TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist. | 2021 Nov 3 |
1 |
| 14 |
31734832 | A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. | 2020 Aug |
2 |
| 15 |
32020437 | Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. | 2020 Oct |
1 |
| 16 |
32167393 | MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. | 2020 May |
2 |
| 17 |
32827690 | Differential mechanisms involved in RG-7388 and Nutlin-3 induced cell death in SJSA-1 osteosarcoma cells. | 2020 Nov |
1 |
| 18 |
33092134 | Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting. | 2020 Oct 20 |
1 |
| 19 |
30511219 | Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients. | 2019 Jan |
1 |
| 20 |
30647052 | BCL2/MDM2 Inhibitor Combo Effective in AML. | 2019 Feb |
1 |
| 21 |
30700046 | Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells. | 2019 Jan 29 |
1 |
| 22 |
31004033 | Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells. | 2019 Dec |
2 |
| 23 |
31062077 | A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors. | 2019 Jul |
1 |
| 24 |
31167802 | Oral idasanutlin in patients with polycythemia vera. | 2019 Aug 8 |
1 |
| 25 |
31568878 | Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy. | 2019 Dec |
1 |
| 26 |
31689961 | The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy. | 2019 Nov 4 |
1 |
| 27 |
29368050 | Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors. | 2018 Mar |
2 |
| 28 |
29392451 | Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML. | 2018 Mar |
2 |
| 29 |
29768700 | Cell- and Tissue-Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin. | 2018 Jul 20 |
1 |
| 30 |
30158012 | Efficient Industrial Synthesis of the MDM2 Antagonist Idasanutlin via a Cu(I)-catalyzed [3+2] Asymmetric Cycloaddition. | 2018 Aug 22 |
2 |
| 31 |
30352966 | Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells. | 2018 Oct 24 |
1 |
| 32 |
30543590 | Novel therapeutic approaches in polycythemia vera. | 2018 Nov |
1 |
| 33 |
28821555 | p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. | 2017 Nov 1 |
1 |
| 34 |
26586447 | Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans. | 2016 Aug |
2 |
| 35 |
26869629 | Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. | 2016 May |
1 |
| 36 |
26993060 | Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388). | 2016 Nov |
2 |
| 37 |
23808545 | Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. | 2013 Jul 25 |
1 |